Drug Profile
SEA CD40
Alternative Names: SEA-1C10; SEA-CD40Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Seattle Genetics
- Developer Merck Sharp & Dohme; Seagen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma; Non-small cell lung cancer
- Phase I Lymphoma; Pancreatic cancer; Solid tumours
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 14 Apr 2023 Seagen and Merck Sharp & Dohme terminate a phase I trial for Lymphoma (Late-stage disease, Monotherapy, Second-line therapy or greater), Solid-tumours (Combination therapy, Late-stage disease) and Solid tumours (Inoperable/unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, SC), due to portfolio prioritization (NCT02376699)
- 19 Dec 2022 Phase I trial is still ongoing for Lymphoma (Late-stage disease, Monotherapy, Second-line therapy or greater), Solid-tumours (Combination therapy, Late-stage disease)and Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, SC) (NCT02376699)